Combined ATR and PARP inhibition has been evaluated across multiple studies; despite promising preclinical data, the phase 2 CAPIRI trial failed to demonstrate a clinical benefit in platinum-resistant epithelial ovarian cancer [129,130]. Here, PARP1 is linked to ovarian carcinoma.